Daré Bioscience Q2 2023 cash $13.3M; auditor resigns; Ovaprene Phase 3 enrollment to start 4Q23

Dare Bioscience, Inc.

Cash and cash equivalents of $13.3M at June 30, 2023; G&A expenses $2.9M, R&D expenses $6.0M.
Auditor Mayer Hoffman McCann P.C. resigned effective upon filing of 2023 10-K or earlier; no disagreements; prior report had going concern paragraph.
XACIATO first commercial sale expected 2H-2023; $1.0M cash received and $1.8M milestone upon first sale from partner Organon.
Ovaprene pivotal Phase 3 contraceptive efficacy study enrollment to start 4Q-2023; U.S. rights licensed to Bayer.
Sildenafil Cream 3.6% positive Phase 2b topline data; preparing end-of-Phase 2 FDA meeting for FSAD/FSIAD.

item 2.02 item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dare Bioscience, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended June 30, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027449

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.